Imunon (IMNN) Projected to Post Quarterly Earnings on Tuesday

Imunon (NASDAQ:IMNN) will likely be releasing its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Imunon to announce earnings of ($0.8675) per share for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 11:00 AM ET.

Imunon (NASDAQ:IMNN) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($1.22) by $0.38. On average, analysts expect Imunon to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Imunon Price Performance

IMNN stock traded down $0.04 during midday trading on Tuesday, reaching $1.49. 7,395 shares of the stock were exchanged, compared to its average volume of 94,854. The stock has a market capitalization of $6.24 million, a PE ratio of -0.29 and a beta of 1.96. Imunon has a 52 week low of $1.47 and a 52 week high of $8.19. The company has a fifty day moving average price of $1.95 and a 200 day moving average price of $2.71.

Analyst Upgrades and Downgrades

IMNN has been the subject of several analyst reports. Maxim Group set a $10.00 price target on shares of Imunon and gave the stock a “buy” rating in a report on Friday, April 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Imunon in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Imunon currently has an average rating of “Hold” and a consensus price target of $10.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Imunon stock. Armistice Capital LLC purchased a new position in shares of Imunon, Inc. (NASDAQ:IMNN) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 266,886 shares of the company’s stock, valued at approximately $1,017,000. Armistice Capital LLC owned approximately 8.69% of Imunon at the end of the most recent quarter. 4.47% of the stock is currently owned by institutional investors and hedge funds.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.